Dr. Reddy's ready for FDA inspection; Biomar Microbial invests €2 million in expansion;

> Dr. Reddy's Laboratories ($RDY), which has been making enhancements to an API plant in Mexico in an effort to get the FDA to lift an import ban, reports that the agency will inspect the facility at the end of the month. Story

> Biomar Microbial Technologies has opened a €2 million ($2.6 million) expansion of its API plant in León, Spain, and will devote nearly all of the 3,000 liter capacity to serving "foreign multinationals." Release

> The European Medicines Agency says that since there have been no safety issues raised about the anti-cancer medicines Caelyx (doxorubicin hydrochloride) and Ceplene (histamine dihydrochloride) manufactured at the troubled Ben Venue Laboratories plant in Bedford, OH, the plant should continue to make them until alternate manufacturing can be established. Release

> Sigma-Aldrich has completed a 57,000 square foot expansion of its Bangalore, India, campus, encompassing a 49,000 square foot distribution facility and an 8,000 square foot packaging area. Story

> The U.K. has made a grant to The Wool Packaging Co. to enhance wool packaging for vaccines in an effort to reduce the amount of wastage in temperature-sensitive products that are often shipped to harsh climates. Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.